External Controls to Study Treatment Effects in Rare Diseases: Challenges and Future Directions

Area of Science:

• Pharmacovigilance
• Clinical Trial Design
• Real-World Evidence

Background:

• Regulatory agencies increasingly use real-world evidence (RWE) from routine healthcare data for novel therapy evaluation.
• External control arms derived from RWE are crucial for augmenting single-arm clinical trials in rare diseases.
• Methodological limitations can impact the validity of RWE-based external control arm comparisons.

Purpose of the Study:

• To review common methodologies for utilizing external control arms in rare disease research.
• To identify and discuss critical methodological challenges associated with these approaches.
• To propose future directions for enhancing the validity of RWE-based external control arms.

Main Methods:

• Literature review of frequently employed methods for constructing external control arms.
• Analysis of key criticisms and limitations reported in existing studies.
• Synthesis of potential solutions and best practices for future research.

Main Results:

• Summarized common approaches for RWE-derived external control arms.
• Highlighted significant methodological concerns impacting data interpretation.
• Identified areas requiring further research and development.

Conclusions:

• External control arms offer valuable insights but require careful methodological consideration.
• Addressing identified criticisms is essential for reliable RWE utilization in rare disease drug evaluation.
• Future research should focus on robust methodologies to ensure the validity of real-world data comparisons.